Physician profile
Abhinav Raina
NPI 1649214974
$5,168.30
in general payments reported to CMS, 2019-2025
26 companies · $1,375 in 2025
The $1,375 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $902 · 2020: $189 · 2021: $503 · 2022: $611 · 2023: $722 · 2024: $867 · 2025: $1,375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,963.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,416.09 | 2019-2025 | Amplatzer Amulet, Gallant, Aveir |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $595.83 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $327.19 | 2019-2025 | |
| Boston Scientific Corporation | $239.72 | 2021-2023 | Watchman Access System |
| Amgen INC. | $168.35 | 2019-2025 | Repatha |
| Kestra Medical Technology Services, INC. | $149.36 | 2025 | Assure Wcd |
| Lexicon Pharmaceuticals, INC. | $148.47 | 2024 | |
| Impulse Dynamics (USA) INC. | $139.67 | 2022 | |
| Chiesi USA, INC. | $101.50 | 2025 | Kengreal |
| Philips North America LLC | $97.49 | 2025 | Eagle Eye |
| Pfizer INC. | $84.72 | 2019-2024 | |
| Edwards Lifesciences Corporation | $71.86 | 2019-2024 | Sapien 3 Ultra Resilia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.79 | 2023-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $67.95 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $63.84 | 2022-2024 | Opsumit, Uptravi |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ekos Corporation | $60.53 | 2019 | |
| Astellas Pharma US INC | $59.09 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $47.88 | 2024 | Wainua |
| Bayer Healthcare Pharmaceuticals INC. | $47.40 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $45.90 | 2023 | Verquvo |
| Regeneron Healthcare Solutions, INC. | $41.69 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $37.86 | 2019 | |
| Heartflow, INC. | $25.76 | 2023 | Ffrct |
| Bridgebio Pharma, INC. | $23.79 | 2025 | Attruby |
| Cordis US Corp. | $19.44 | 2025 | Mynx Control Venous |
| Lundbeck LLC | $15.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abhinav Raina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.